Hoth Therapeutics Inc
Company Profile
Business description
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA). Its current assets are focused in treating cancer, skin toxicities, Alzheimer's, and weight loss.
Contact
720 Monroe Street
Suite E514
HobokenNJ07030
USAT: +1 866 239-7459
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
3
Stocks News & Analysis
stocks
After earnings, is Microsoft a buy, a sell, or fairly valued?
stocks
Albemarle earnings: Shares rally on strong profit growth well above consensus estimates
stocks
Ahead of IPOs, AI giants keep making circular deals. Here’s why that’s a risk - Clone
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,980.50 | 31.60 | -0.35% |
| CAC 40 | 8,120.66 | 81.42 | -0.99% |
| DAX 40 | 24,365.72 | 297.89 | -1.21% |
| Dow JONES (US) | 49,739.72 | 142.75 | 0.29% |
| FTSE 100 | 10,248.64 | 28.31 | -0.28% |
| HKSE | 26,393.71 | 232.57 | -0.87% |
| NASDAQ | 26,101.38 | 295.18 | 1.14% |
| Nikkei 225 | 62,713.65 | 120.19 | -0.19% |
| NZX 50 Index | 13,175.13 | 95.48 | -0.72% |
| S&P 500 | 7,391.25 | 54.14 | 0.74% |
| S&P/ASX 200 | 8,744.40 | 36.40 | -0.41% |
| SSE Composite Index | 4,179.95 | 0.14 | -0.00% |